Sudarshan Pharma Industries Limited (SPIL) has made significant strides in its expansion plans, securing approval for project relocation and strategically investing in an operational API facility. These developments mark important milestones in the company's growth strategy.

Project Relocation and Timeline Extension

Sudarshan Pharma has obtained approval to relocate its Vitamin B6 and B1 greenfield projects from MIDC, Maharashtra to GIDC, Gujarat. The company cited local resistance issues at the original location as the reason for the change. Along with the relocation approval, the Department of Pharmaceuticals has extended the Scheme Commencement of Production (SCOP) timeline to December 31, 2027.

This extension provides Sudarshan Pharma with additional time to set up its greenfield projects for Vitamin B6 and Vitamin B1 production. The company had initially requested an extension until June 30, 2026, for using existing units in GIDC, or until December 31, 2027, for setting up fresh projects on new land.

Strategic Investment in API Facility

In a separate development, Sudarshan Pharma has announced a significant strategic investment to boost its manufacturing capacity. The company has signed a definitive agreement with Srigen Lifesciences Private Limited for the transfer of capital assets, including land, building, and plant & machinery, at a fully operational manufacturing facility in Telangana.

Key points of the investment include:

• Investment Value: Rs. 25.50 crore
• Location: Strategic location in Telangana - 501401
• Capacity Enhancement: The facility adds instant production capacity, accelerating supply chain responsiveness and overall throughput.
• Product Portfolio Expansion: The acquired facility is capable of producing complex, high-margin molecules, enhancing SPIL's offerings in global therapeutic markets.

Strategic Benefits

The investment in the operational API facility is expected to yield several strategic benefits for Sudarshan Pharma:

1. Immediate Manufacturing Scale-Up: The acquisition provides instant production capacity, improving supply chain responsiveness.
2. Faster Time-to-Market: With existing infrastructure and regulatory frameworks, SPIL can significantly reduce product launch timelines.
3. Expanded Product Portfolio: The facility enables production of high-value, technically complex pharmaceutical ingredients.
4. Regulatory Advantage: The facility's proven compliance track record is expected to shorten approval cycles and lower regulatory costs.

Executive Commentary

Sachin Mehta, Joint Managing Director & Chief Financial Officer of SPIL, commented on the investment: "This investment represents a pivotal milestone in Sudarshan Pharma's growth agenda. It not only strengthens our manufacturing backbone but also significantly enhances our ability to serve global markets with agility, quality, and regulatory compliance. This addition is expected to contribute meaningfully to both revenue and profitability, supporting our financial performance and long-term shareholder value creation."

These developments demonstrate Sudarshan Pharma's commitment to expanding its manufacturing capabilities and strengthening its position in the pharmaceutical and specialty chemicals sectors. The company's focus on vertical integration, operational efficiency, and product diversification is likely to drive its growth in both domestic and global markets.

Sudarshan Pharma Industries Limited (SPIL) has made a strategic move to enhance its manufacturing capabilities in the pharmaceutical sector. The company has invested ₹25.5 crore to acquire an operational Active Pharmaceutical Ingredient (API) facility located in Telangana, signing a definitive agreement with Srigen Lifesciences Private Limited for the transfer of capital assets.

Strategic Acquisition Details

The acquisition includes land, buildings, and plant & machinery at a fully operational manufacturing facility situated in a strategic location in Telangana. This high-impact move is expected to result in significant growth in SPIL's manufacturing capacity and accelerate its trajectory in the high-growth API and specialty chemicals sectors.

Expansion of Product Portfolio

The newly acquired facility is capable of producing complex, high-margin molecules, which will enhance SPIL's offerings in global therapeutic markets. Some of the key APIs and intermediates that can be produced at this facility include:

• Ropivacaine
• Bupivacaine
• Probenecid (Probalan)
• Sitagliptin
• Apixaban
• Rivaroxaban

These products have strong demand across regulated and semi-regulated markets, positioning SPIL for expanded market presence.

Strategic Benefits

The acquisition brings several strategic advantages to Sudarshan Pharma:

1. Immediate Manufacturing Scale-Up: The facility adds instant production capacity, improving supply chain responsiveness and overall throughput.
2. Faster Time-to-Market: With established infrastructure and regulatory frameworks, SPIL can significantly reduce product launch timelines compared to greenfield projects.
3. Regulatory Advantage: The facility's proven compliance track record and comprehensive regulatory documentation are expected to shorten approval cycles and lower regulatory costs.

Management Commentary

Sachin Mehta, Joint Managing Director & Chief Financial Officer of SPIL, commented on the acquisition: "This investment represents a pivotal milestone in Sudarshan Pharma's growth agenda. It not only strengthens our manufacturing backbone but also significantly enhances our ability to serve global markets with agility, quality, and regulatory compliance. This addition is expected to contribute meaningfully to both revenue and profitability, supporting our financial performance and long-term shareholder value creation."

About Srigen Lifesciences

Srigen Lifesciences, established in 2010, is a research-driven pharmaceutical company specializing in the development, manufacturing, and commercialization of advanced API Key Starting Materials (KSMs) and intermediates. The company operates a well-equipped facility with an 80-kilolitre reactor capacity, supporting medium- to large-scale, multi-product manufacturing under stringent quality, safety, and regulatory standards.

Conclusion

This strategic investment by Sudarshan Pharma Industries Limited marks a significant step in the company's expansion plans. By acquiring an operational API facility, SPIL is poised to strengthen its position in the pharmaceutical and specialty chemicals market, both domestically and globally. The move aligns with the company's long-term strategy to build a robust, scalable, and compliance-driven manufacturing infrastructure, supporting its global expansion efforts and driving sustained value creation for stakeholders.